Physician profile
Danielle Butler
NPI 1184800344
$1,063.67
in general payments reported to CMS, 2019-2025
21 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.86 · 2023: $364 · 2024: $317 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,048.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $143.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $125.29 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $109.90 | 2023-2025 | Farxiga, Airsupra |
| Abbvie INC. | $65.15 | 2023-2025 | Vraylar, Ubrelvy |
| Dexcom, INC. | $64.45 | 2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $59.87 | 2024-2025 | Voquezna |
| Amgen INC. | $56.66 | 2023-2024 | Otezla, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $56.53 | 2025 | Spravato |
| Corcept Therapeutics | $56.22 | 2023-2024 | Korlym |
| Lilly USA, LLC | $54.83 | 2023-2025 | Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $37.24 | 2023 | |
| Pfizer INC. | $35.61 | 2024-2025 | |
| Sage Therapeutics, LLC | $35.37 | 2025 | Zurzuvae |
| Glaxosmithkline, LLC. | $30.50 | 2024-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.53 | 2023 | Xifaxan |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $24.95 | 2025 | Rexulti |
| Inspire Medical Systems, INC. | $18.08 | 2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $17.21 | 2023 | Austedo |
| Genentech USA, INC. | $14.86 | 2020 | |
| Esperion Therapeutics, INC. | $14.18 | 2023 | Nexletol |
| Lundbeck LLC | $13.88 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.